Arbutus Biopharma (ABUS) Cash from Operations (2013 - 2026)

Arbutus Biopharma has disclosed Cash from Operations across 14 years of filings, most recently posting 8110000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 8110000.0, up 39.44% year-over-year; the trailing twelve-month figure through Mar 2026 was 34356000.0 (up 41.72% YoY), and the FY2025 annual result was 39637000.0, up 38.88% from the prior year.
• Cash from Operations came in at 8110000.0 for Q1 2026 at Arbutus Biopharma, down from 4680000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 20619000.0 in Q1 2022 to a low of 27301000.0 in Q1 2023.
• The 5-year median for Cash from Operations is 16990000.0 (2022), against an average of 13758176.47.
• Across the five-year window, Cash from Operations surged 215.31% in 2022 and tumbled 232.41% in 2023, its largest moves.
• Arbutus Biopharma's Cash from Operations stood at 16990000.0 in 2022, then decreased by 1.78% to 17292000.0 in 2023, then soared by 40.35% to 10315000.0 in 2024, then surged by 54.63% to 4680000.0 in 2025, then slumped by 73.29% to 8110000.0 in 2026.
• The last three Cash from Operations figures came in at 8110000.0 (Q1 2026), 4680000.0 (Q4 2025), and 5817000.0 (Q3 2025), per Business Quant data.